Acadia Names Konstantina Katcheves as Senior VP, Chief Business & Strategy Officer

Acadia Pharmaceuticals Inc. appointed Konstantina “Tina” Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia.

Katcheves brings over two decades of experience in the biopharmaceutical industry, spanning corporate strategy, M&A, and innovation leadership. Most recently, she served as Senior Vice President, Global Business Development at Teva Pharmaceuticals, where she oversaw the expansion of Teva’s innovative medicines pipeline and built new internal and external capabilities to support long-term portfolio advancement. 

Before Teva, she held multiple senior executive roles at Bristol Myers Squibb (BMS), including Interim Head of Enterprise Strategy and Business Development. At BMS, she led the acquisition of Karuna Therapeutics and drove over $18 billion in transactions, supporting near-term revenue growth and long-term pipeline innovation. Before BMS, she held senior strategic roles at Agilent Technologies and Lonza Group.

“Tina brings a wealth of experience in global business development and strategic partnerships that will be instrumental as we continue to expand our pipeline and pursue high-impact growth opportunities,” said Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals. “Her leadership and deep industry knowledge will be invaluable as we advance our mission to improve the lives of patients affected by neurological and rare disease.”